Clinical trials: Pituitary Dwarfism
Growth Hormone Deficiency, Attention Deficit Disorder
The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents
Analysis of the short-and long-term impact of recombinant growth hormone on attention deficit and hyperactivity charachteristics in children and adolescents.
- Conditions
- Growth Hormone Deficiency, Attention Deficit Disorder, Idiopathic Short Stature
- Trial name
- NCT02973061
- Testing
- Questionnaires
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assaf-Harofeh Medical Center
Growth Hormone Deficiency
Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels
The METAB-BELGROW-LAGH study aims to prospectively evaluate the metabolic outcomes of Belgian children diagnosed with growth hormone deficiency (GHD) over a three-year period following the initiation of treatment with either…
- Trial name
- METAB-BELGROW (NCT07173036)
- Testing
- metabolic and auxological outcomes
- Volunteers
- 300 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
This trial is conducted in Japan. This protocol describes an extension trial to supply hGH to subjects who wish continuous treatment after the long-term Phase 3 trial (GHLiquid-1519) until hGH products have been approved for GHDA…
- Trial name
- NCT00184730
- Testing
- somatropin
- Where
- Japan
- Volunteers
- 86 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency (GHD)
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
This is a Multi-national Trial. The Goal of the Trial is to Offer Subjects Who Complete 12 Months in the LUM-201-10 Phase 3 Trial up to an Additional 36 Months of Treatment of LUM-201 While Evaluating Safety and Tolerability of…
- Trial name
- NCT07129759
- Testing
- LUM-201
- Volunteers
- 150 people
- Sponsor
- Lumos Pharma
Obesity, GHD
Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity
Obesity and obesity-related diseases have reached epidemic proportions in Western countries (1-3). Laparoscopic-adjustable silicone gastric banding (LASGB) is a purely restrictive operation that determine effective weight loss…
- Trial name
- GH&LASGB (NCT00553852)
- Testing
- Recombinant GH Saizen (Merck-Serono)
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Federico II University
Obesity, Short Stature
Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children
Background: Overweight and obese children and adults often have lower levels of growth hormone in the blood. Regulation of growth hormone may be tied to weight and free fatty acids in the blood.
- Conditions
- Obesity, Short Stature, Growth Hormone Deficiency
- Trial name
- NCT01237041
- Testing
- Niacin First, Dose-Establishing Study 1 Niacin 250mg, Dose-Establishing Study 1 Niacin 500mg
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Healthy
ATS-1 Needle Free Injection Device Study-a Device for Administering r-hGH (Saizen) to Treat Growth Hormone Deficiency
This study was a Phase I, open label, randomized, 2-period, 2-sequence, crossover study designed to assess the relative bioavailability of Saizen administered by the ATS-1 needle-free injection device and a standard needle and…
- Trial name
- NCT00407472
- Testing
- ATS-1 needle free device
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- EMD Serono
Growth Hormone Deficiency, Dwarfism
rhGH Therapy on Hepatic Drug Metabolism
The purpose of the study is to understand the effect of rhGH therapy on hepatic drug metabolism in children with idiopathic growth hormone deficiency.
- Trial name
- NCT00458991
- Testing
- Dextromethorphan and Caffeine
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Louisville
Growth Hormone Deficiency, Turner's Syndrome
Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device
The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or…
- Trial name
- ZOMAXEPT (NCT02018172)
- Testing
- somatropin
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Ferring Pharmaceuticals
Growth Hormone Deficiency
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency
To evaluate the safety and efficacy of PEG Somatropin Injection in the treatment of children with growth hormone deficiency, as well as to study the feasibility of extending the dosing intervals (once per two weeks) of PEG…
- Trial name
- NCT02976675
- Testing
- PEG-somatropin
- Where
- 24 sites in China
- Volunteers
- 600 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Growth Hormone Deficiency
IGF1 Generation Test
To assess the predictive value of the short term IGF-1 stimulation test, based on IGF-1 changes, on the 24 months growth response to 2 different doses of GH in patients with conventional GH deficiency.
- Trial name
- CAREL (NCT00145457)
- Testing
- Blood sample, Radiography
- Where
- 8 sites in France
- Volunteers
- 82 people
- Sponsor
- Pfizer
Growth Hormone Deficiency
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency
To Evaluate the safety and efficacy of PEG Somatropin in the treatment of children with growth hormone deficiency, as well as to study the dosage of PEG Somatropin.
- Trial name
- NCT03249480
- Testing
- PEG-somatropin
- Where
- 28 sites in China
- Volunteers
- 900 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Growth Hormone Deficiency
Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
This study will recruit healthy controls (who have normal GH production and growth hormone levels) and patients identified as having GHD, who are deemed eligible for GH replacement therapy according to NICE guidelines.
- Trial name
- NCT02243852
- Testing
- Growth Hormone Replacement Therapy
- Where
- 2 sites in United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Liverpool
Growth Hormone Deficiency (GHD)
Treatment of Children With Insufficient Secretion of Growth Hormone
The purpose of this study is to compare a new weekly administered growth hormone preparation with standard daily treatment in children with insufficient secretion of growth hormone
- Trial name
- BPLG-004 (NCT00271518)
- Testing
- growth hormone (somatropin)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- LG Life Sciences
Adult Growth Hormone Deficiency
MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)
This study aims to assess the safety, tolerability and Pharmacokinetics/ Pharmacodynamics (PK/PD) profile of three doses of MOD-4023 on a weekly regime and one dose on an every-other-week regime administered for a period of 4…
- Trial name
- NCT01225666
- Testing
- MOD-4023
- Where
- 15 sites in Czechia, Hungary and 4 more
- Volunteers
- 52 people
- Sponsor
- OPKO Health, Inc.
Growth Hormone Deficiency
Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects…
- Trial name
- OraGrowtH210 (NCT04614337)
- Testing
- LUM-201, rhGH Norditropin® pen (34 µg/kg)
- Where
- 43 sites in United States, Australia and 4 more
- Volunteers
- 104 people
- Sponsor
- Lumos Pharma
Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
We, the researchers, are following the natural history of Albright hereditary osteodystrophy. We have found that growth hormone deficiency is very common in patients with pseudohypoparathyroidism type 1A, which falls under the…
- Conditions
- Pseudohypoparathyroidism Type 1A, Albright Hereditary Osteodystrophy, Pseudopseudohypoparathyroidism
- Trial name
- NCT00209235
- Testing
- Neurocognitive and psychosocial testing
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Connecticut Children's Medical Center
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
This study is conducted in Europe. The aim of this study is to compare the easiness of use of Norditropin NordiFlex® device to the device previously used by patients or parents.
- Conditions
- Growth Hormone Disorder, Growth Hormone Deficiency in Children, Foetal Growth Problem, Small for Gestational Age
- Trial name
- NCT01245374
- Testing
- Norditropin NordiFlex®
- Where
- France
- Volunteers
- 103 people
- Sponsor
- Novo Nordisk A/S
Adult Growth Hormone Deficiency
A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency
This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).
- Trial name
- NCT01909479
- Testing
- MOD-4023
- Where
- Israel
- Volunteers
- 202 people
- Sponsor
- OPKO Health, Inc.
Growth Hormone Disorder, Adult Growth Hormone Deficiency
An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®
This observational study is conducted in Europe. The aim of this observational study is to investigate the changes in a score (GET-score) which includes quality of life, body composition and cholesterol metabolism in patients on…
- Trial name
- GET (NCT00934063)
- Testing
- somatropin, No treatment given
- Where
- Germany
- Volunteers
- 121 people
- Sponsor
- Novo Nordisk A/S